Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Purpose<br/> Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. <br/><br/>Methods<br/> We compared the efficacy and safety of evolocumab in hypercholesterolemic...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer Verlag
2016
|